In June 2016, NICE reviewed this guidance and it is recommended that it is moved to the static list.  Please find the published review decision here.

Please refer to the updated CG92 for recommendations on neuromuscular stimulation devices in patients admitted for a stroke. 

Next review: June 2021

NICE has developed medical technology guidance on the geko device.

NICE medical technologies guidance addresses specific technologies notified to NICE by manufacturers. The ‘case for adoption’ recommendations are based on the claimed advantages of introducing the specific technology compared with current management of the condition. This ‘case’ is reviewed against the evidence submitted and expert advice. If the case for adopting the technology is supported, then the technology has been found to offer advantages to patients and the NHS. The specific recommendations on individual technologies are not intended to limit use of other relevant technologies which may offer similar advantages.

NICE has said that the geko device can be used for people in whom it is not possible to use other methods of preventing blood clots.

Coding relevant to this guidance

OPCS-4

A70.8 Other specified neurostimulation of peripheral nerve

Z12.1 Popliteal nerve

SNOMED CT

Procedure:

840581000000109 | Functional electrical stimulation of common peroneal nerve (procedure)

Existing concept

963431000000102 | Application of neuromuscular electrical stimulation device (procedure)

Device:

463008001 | Physical therapy electrical stimulation system, battery-powered (physical object)

12234301000001109 | Geko physical therapy electrical stimulation system (Firstkind Ltd.) (physical object)

Your responsibility

This guidance represents the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, healthcare professionals are expected to take this guidance fully into account. However, the guidance does not override the individual responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

Commissioners and/or providers have a responsibility to implement the guidance, in their local context, in light of their duties to have due regard to the need to eliminate unlawful discrimination, advance equality of opportunity, and foster good relations. Nothing in this guidance should be interpreted in a way that would be inconsistent with compliance with those duties.

Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible.

  • National Institute for Health and Care Excellence (NICE)